South San Francisco, California, August 20, 2025 – Synlico Inc., is proud to announce that its article, “Causal Graphs: A Blueprint Driving Drug Discovery from Single-Cell Omics”, has been featured in the latest issue of Life Science Insights, a quarterly magazine that explores the latest thought leadership from California, highlighting recognition of Synlico’s innovative approach.
The article explains why Synlico employs AI models using causal-graph representations as the backbone to pinpoint disease-driving interactions, nominate novel targets, and design mechanism-guided therapies, integrating causal discovery and inference, generative modeling, and single-cell bioinformatics. To supply the required diversity and statistical power, Synlico aggregates large-scale primary patient scRNA-seq datasets – more than 100 million cells from around 18,000 patients. This comprehensive database with Synlico’s cutting-edge AI model enables mapping of context-specific gene–gene edges, and prediction of how perturbing a driver gene reverberates through downstream pathways.
Synlico is honored to contribute to this important conversation and share our perspective alongside other industry leaders.
Read the full article here: Causal Graphs: A Blueprint Driving Drug Discovery from Single-Cell Omics
About Synlico inc.
Synlico focuses on discovering and developing innovative therapies by establishing causality, making cellular processes explainable, predictable, and engineerable. We combine generative model with causal structure discovery & inference and employ our AI models on a carefully curated comprehensive patients’ single-cell transcriptomics database. Our proprietary AI models identify causal relations between genes and quantify effects of any gene interventions on downstream targets directly in patients. We are applying our platform for novel mechanism/target discovery and causality-aided drug development. Visit www.synlico.com to find out more.
Synlico Inc. contacts:
Linda Guo
